Influenza Virus Patents (Class 424/206.1)
-
Patent number: 8258106Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: GrantFiled: November 10, 2006Date of Patent: September 4, 2012Assignees: University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The United States of America, as represented by the Department of Health and Human ServicesInventors: Arthur M. Krieg, Joel N. Kline, Dennis Klinman, Alfred D. Steinberg
-
Publication number: 20120171243Abstract: Disclosed is an attenuation method of an influenza virus, that is, a reassortant virus and a preparation method thereof. The disclosed reassortant virus has, in a ratio of 6:2, genes encoding a recombinant non-toxic protein and a wild type non-toxic protein, and genes encoding toxic proteins, HA (hemagglutinin) and NA (neuraminidase), of an influenza virus, the recombinant non-toxic protein consisting of a substituted caspase recognition sequence without a change of a protein size within the wild type non-toxic protein of the influenza virus. The disclosed attenuated influenza virus shows a high attenuation without a reduction of productivity in a fertilized egg. Accordingly, the method can be used as an economically efficient live vaccine preparation method which has both safety and efficiency and can use a fertilized egg as a production system.Type: ApplicationFiled: August 22, 2011Publication date: July 5, 2012Applicant: Industry-Academic Cooperation Foundation, Yonsei UniversityInventors: Baik Lin Seong, Yo Han Jang, Kwang Hee Lee, Young Ho Byun
-
Patent number: 8202967Abstract: The present invention relates to novel hemagglutinin H5 proteins, nucleic acids and vectors encoding for those as well as vaccines comprising any of such H5 proteins, nucleic acids or vectors encoding for those H5 proteins. Moreover, the present invention also relates to the medicinal use of any of such compositions in humans and animals.Type: GrantFiled: October 24, 2007Date of Patent: June 19, 2012Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Eric Vaughn, Paulino Carlos Gonzalez-Hernandez, Juergen Däemmgen
-
Patent number: 8137676Abstract: The present invention relates, in general, to attenuated equine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated equine influenza viruses having modifications to an equine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: June 1, 2005Date of Patent: March 20, 2012Assignees: Mount Sinai School of Medicine, University of KentuckyInventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Chambers
-
Patent number: 8133723Abstract: An aspect of the present invention is directed towards DNA plasmid vaccines capable of generating in a mammal an immune response against a plurality of influenza virus subtypes, comprising a DNA plasmid and a pharmaceutically acceptable excipient. The DNA plasmid is capable of expressing a consensus influenza antigen in a cell of the mammal in a quantity effective to elicit an immune response in the mammal, wherein the consensus influenza antigen comprises consensus hemagglutinin (HA), neuraminidase (NA), matrix protein, nucleoprotein, M2 ectodomain-nucleo-protein (M2e-NP), or a combination thereof. Preferably the consensus influenza antigen comprises HA, NA, M2e-NP, or a combination thereof. The DNA plasmid comprises a promoter operably linked to a coding sequence that encodes the consensus influenza antigen. Additionally, an aspect of the present invention includes methods of eliciting an immune response against a plurality of influenza virus subtypes in a mammal using the DNA plasmid vaccines provided.Type: GrantFiled: June 10, 2011Date of Patent: March 13, 2012Assignee: The Trustees of The University of PennsylvaniaInventors: Ruxandra Draghia-Akli, David B Weiner, Jian Yan, Dominick J Laddy
-
Patent number: 8129499Abstract: The present disclosure generally relates to peptides having antiviral properties. More particularly, the invention relates to peptides exhibiting activity against influenza viruses, to pharmaceutical compositions comprising the peptides, and to methods of using the peptides to prevent and/or treat influenza viral infections.Type: GrantFiled: June 15, 2009Date of Patent: March 6, 2012Assignee: Wisconsin Alumni Research FoundationInventors: Stacey L. Schultz-Cherry, Curtis R. Brandt, Jeremy C. Jones
-
Patent number: 8129351Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: GrantFiled: February 25, 2005Date of Patent: March 6, 2012Assignees: The University of Iowa Research Foundation, Coley Pharmaceutical Group, Inc., The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Arthur M. Krieg, Dennis Klinman, Alfred D. Steinberg
-
Patent number: 8124101Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: June 1, 2005Date of Patent: February 28, 2012Assignees: Mount Sinai School of Medicine, St. Jude Children's Research Hospital, The United States of America as represented by The Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Patent number: 8119337Abstract: Influenza viruses for use in preparing human vaccines have traditionally been grown on embryonated hen eggs, although more modern techniques grow the virus in mammalian cell culture e.g. on Vero, MDCK or PER.C6 cell lines. The inventor has realized that the conditions used for influenza virus 5 culture can increase the risk that pathogens other than influenza virus may grow in the cell lines and have identified specific contamination risks. Suitable tests can thus be performed during manufacture in order to ensure safety and avoid iatrogenic infections.Type: GrantFiled: September 9, 2005Date of Patent: February 21, 2012Inventor: Jens-Peter Gregersen
-
Patent number: 8114415Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. A method of producing a cold adapted (ca) influenza virus that replicates efficiently at, e.g., 25° C. (and immunogenic compositions comprising the same) is also provided.Type: GrantFiled: October 20, 2008Date of Patent: February 14, 2012Assignee: Medimmune, LLCInventors: Erich Hoffmann, Hong Jin, Bin Lu, Gregory Duke, George Kemble, Zhongying Chen
-
Publication number: 20120034265Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: September 28, 2011Publication date: February 9, 2012Applicant: MEDIMMUNE, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20120034264Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: June 16, 2011Publication date: February 9, 2012Applicant: MedImmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Publication number: 20120020997Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided.Type: ApplicationFiled: August 19, 2011Publication date: January 26, 2012Inventors: Erich Hoffman, Hong Jin, Bin Lu, Greg Duke, George Kemble
-
Publication number: 20120009215Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: September 12, 2011Publication date: January 12, 2012Inventors: Chin-Fen Yang, George Kemble
-
Patent number: 8093033Abstract: Vectors and methods for the production of influenza viruses suitable as recombinant influenza vaccines in cell culture are provided. Bi-directional expression vectors for use in a multi-plasmid influenza virus expression system are provided. Additionally, the invention provides methods of producing influenza viruses with enhanced ability to replicate in embryonated chicken eggs and/or cells (e.g., Vero and/or MDCK) and further provides influenza viruses with enhanced replication characteristics. In addition, the present invention includes an improved method of rescue, wherein animal cells (e.g., SF Vero cells) are electroporated with plasmids and vectors of the invention.Type: GrantFiled: December 16, 2008Date of Patent: January 10, 2012Assignee: Medimmune, LLCInventors: George Kemble, Gregory Duke
-
Patent number: 8088393Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: June 24, 2010Date of Patent: January 3, 2012Assignee: MedImmune, LLCInventor: Hong Jin
-
Patent number: 8080255Abstract: The present invention discloses and claims virus like particles (VLPs) that express and/or contains seasonal influenza virus proteins, avian influenza virus proteins and/or influenza virus proteins from viruses with pandemic potential. The invention includes vector constructs comprising said proteins, cells comprising said constructs, formulations and vaccines comprising VLPs of the inventions. The invention also includes methods of making and administrating VLPs to vertebrates, including methods of inducing substantial immunity to either seasonal and avian influenza, or at least one symptom thereof.Type: GrantFiled: October 18, 2006Date of Patent: December 20, 2011Assignee: Novavax Inc.Inventors: Gale Smith, Rick Bright, Peter Pushko, Jinyou Zhang, Kutub Mahmood
-
Patent number: 8058249Abstract: Nucleic acids containing unmethylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response and to redirect a Th2 response to a Th1 response in a subject are disclosed. Methods for treating atopic diseases, including atopic dermatitis, are disclosed.Type: GrantFiled: July 16, 2004Date of Patent: November 15, 2011Assignees: University of Iowa Research Foundation, United States of America as represented by the Department of Health and Human Services, Coley Pharmaceutical Group, Inc.Inventors: Arthur M. Krieg, Joel Kline, Dennis Klinman, Alfred D. Steinberg
-
Patent number: 8057803Abstract: The present invention relates, in general, to attenuated negative-strand RNA viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. The invention also relates to the development and use of IFN-deficient systems for selection of such attenuated viruses. In particular, the invention relates to attenuated influenza viruses having modifications to the NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. The mutant viruses replicate in vivo but demonstrate reduced pathogenicity, and therefore are well suited for live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: April 22, 2008Date of Patent: November 15, 2011Assignee: Mount Sinai School of MedicineInventors: Peter Palese, Adolfo Garcia-Sastre, Thomas Muster
-
Patent number: 8057806Abstract: A method to prepare viruses lacking ion channel activity is provided.Type: GrantFiled: January 26, 2005Date of Patent: November 15, 2011Assignee: Wisconsin Alumni Research FoundationInventor: Yoshihiro Kawaoka
-
Patent number: 8048430Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: September 7, 2010Date of Patent: November 1, 2011Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20110262481Abstract: The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No.1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.Type: ApplicationFiled: December 18, 2009Publication date: October 27, 2011Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AGInventors: Thomas Muster, Markus Wolschek, Andrej Egorov, Elisabeth Roethl, Julia Romanova, Michael Bergmann
-
Patent number: 8043856Abstract: The invention provides adenovirus and retrovirus vectors useful to prepare influenza virus. Also provided is a canine RNA polymerase I promoter and vectors having that promoter.Type: GrantFiled: June 13, 2008Date of Patent: October 25, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Makoto Ozawa
-
Patent number: 8039002Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: August 9, 2007Date of Patent: October 18, 2011Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Publication number: 20110212117Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: July 9, 2009Publication date: September 1, 2011Inventors: Chin-Fen Yang, George Kemble
-
Publication number: 20110212128Abstract: Described herein are influenza virus-like particles (VLPs) that display on truncated, re-engineered or remodeled HA molecules on their surface. Also described are methods of making and using these VLPs.Type: ApplicationFiled: February 18, 2011Publication date: September 1, 2011Applicant: TechnoVax, Inc.Inventors: Jose M. Galarza, George R. Martin
-
Patent number: 8007999Abstract: The present invention provides system and methods for detecting an analyte indicative of an influenza viral infection in a sample of bodily fluid. The present invention also provides for systems and method for detection a plurality of analytes, at least two of which are indicative of an influenza viral infection in a sample of bodily fluid.Type: GrantFiled: May 9, 2007Date of Patent: August 30, 2011Assignee: Theranos, Inc.Inventors: Elizabeth A. Holmes, Ian Gibbons
-
Patent number: 8003106Abstract: Human, humanized and chimeric monoclonal antibodies that bind to influenza M2 protein. The antibodies are useful for, among other things, treatment, diagnostics, purifying and isolating M2 or influenza virus, and identifying the presence of M2 or influenza virus in a sample or a subject.Type: GrantFiled: February 28, 2008Date of Patent: August 23, 2011Assignee: Kyowa Hakko Kirin Co., Ltd.Inventors: Toshifumi Mikayama, Rongfang Wang, Shinichiro Kato
-
Publication number: 20110200635Abstract: Current approaches to influenza vaccination focus either on seasonal strains or pandemic strains. Current seasonal vaccines typically include antigens from two influenza A strains (H1N1 and H3N2) and one influenza B strain. Current pandemic vaccines focus on H5N1 influenza A virus strains. It is an object of the invention to provide further and improved ways of preparing vaccines that can raise immunity against both seasonal and pandemic strains.Type: ApplicationFiled: June 12, 2009Publication date: August 18, 2011Inventors: Angelika Banzhoff, Ralf Leo Clemens
-
Publication number: 20110189230Abstract: H5N1 influenza viruses isolated from animals and humans since 2003 separate into distinct clades based on hemagglutinin amino acid sequences. According to the invention, multiple clades are used in influenza immunization. Thus there is a prime-boost immunization schedule where a subject receives a priming dose of a first clade of H5 influenza A virus and a boosting dose of a second clade of H5 influenza A virus. There is also an immunogenic composition comprising hemagglutinin antigens from more than one clade of H5 influenza A virus.Type: ApplicationFiled: November 25, 2008Publication date: August 4, 2011Applicant: Novartis Vaccines and Diagnostics SRLInventors: Audino Podda, Rino Rappuoli
-
Publication number: 20110182936Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: March 31, 2011Publication date: July 28, 2011Inventors: Chin-Fen Yang, George Kemble, Kanta Subbarao, Brian Murphy
-
Patent number: 7981429Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided.Type: GrantFiled: March 6, 2009Date of Patent: July 19, 2011Assignee: Medimmune, LLCInventors: Chin-Fen Yang, George Kemble
-
Publication number: 20110162982Abstract: An improved method for the manufacture of an oil-in-water emulsion involves three procedures: (i) preparation of a preliminary emulsion; (ii) microfluidization of the preliminary emulsion to reduce its droplet size; and (iii) filtration of the microfluidized emulsion through a hydrophilic membrane. The emulsions are useful as vaccine adjuvants.Type: ApplicationFiled: December 3, 2010Publication date: July 7, 2011Applicant: Novartis Vaccines and Diagnostic, GmbH & Co. KGInventors: Gottfried Kraus, Robert Eskes
-
Patent number: 7968101Abstract: The invention provides a composition useful to prepare influenza viruses, e.g., in the absence of helper virus, using vectors which include tandem transcription cassettes containing PolI and/or PolII promoters.Type: GrantFiled: November 18, 2005Date of Patent: June 28, 2011Assignee: Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann
-
Publication number: 20110142912Abstract: The present invention relates to the use of a lipid vesicle for the preparation of a medicament. The invention further relates to a method of treating and/or preventing a disease or disorder involving administering such a lipid vesicle to an animal in need thereof.Type: ApplicationFiled: December 31, 2007Publication date: June 16, 2011Inventors: Christian Moser, Andreas Kammer, Rinaldo Zurbriggen
-
Patent number: 7959931Abstract: Antigen and adjuvant components of an adjuvanted influenza vaccine are not mixed during manufacture, but are provided as separate components for extemporaneous mixing at the time of use, for example as a kit comprising (i) an antigen component, comprising an influenza virus antigen; and (ii) an adjuvant component, comprising an aluminium salt.Type: GrantFiled: November 6, 2006Date of Patent: June 14, 2011Assignee: Novartis AGInventors: Anthony Colegate, Philip Sizer
-
Patent number: 7959929Abstract: The subject invention pertains to isolated influenza virus that is capable of infecting canids and causing respiratory disease in the canid. The subject invention also pertains to compositions and methods for inducing an immune response against an influenza virus of the present invention. The subject invention also pertains to compositions and methods for identifying a virus of the invention and diagnosing infection of an animal with a virus of the invention.Type: GrantFiled: October 19, 2006Date of Patent: June 14, 2011Assignees: University of Florida Research Foundation, Inc., Cornell Research Foundation, Inc., The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention, Intervet International B.V.Inventors: Patti C. Crawford, Paul J. Gibbs, Edward J. Dubovi, Ruben Omar Donis, Jacqueline Katz, Alexander I. Klimov, Nallakannu P. Lakshmanan, Melissa Anne Lum, Daniel Ghislena Emiel Goovaerts, Mark William Mellencamp, Nancy J. Cox, William L. Castleman
-
Patent number: 7959930Abstract: The invention relates to the field of influenza vaccine production. Influenza vaccines have been produced in embryonated hens' eggs for over 50 years, but recently there have been considerable efforts to develop cell culture systems for vaccine production. The invention provides a nucleic acid comprising an influenza gene segment and a bacteriophage polymerase promotor or a complementary strand of said nucleic acid, and a cell comprising such a nucleic acid capable of producing desired influenza virus. Furthermore, the invention provides a composition comprising a cell or material derived from a cell according to the invention and a virus or material derived from a viral particle according to the invention.Type: GrantFiled: December 22, 2005Date of Patent: June 14, 2011Assignee: Abbott Biologicals B.V.Inventors: Emmie De Wit, Monique I. J. Spronken, Ron A. M. Fouchier, Albert D. M. E. Osterhaus
-
Patent number: 7959927Abstract: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response specific to Mycoplasma hyopneumoniae bacterin and including cell-mediated immunity and local (secretory IgA) immunity. In a preferred embodiment, the adjuvant mixture comprises an acrylic acid polymer, most preferably CARBOPOL®, and a mixture of a metabolizable oil such as one or more unsaturated terpene hydrocarbons, preferably squalene or squalane, and a polyoxyethylene-polypropylene block copolymer such as PLURONIC®. The vaccine composition may optionally include a preservative, preferably thimerosal and/or EDTA.Type: GrantFiled: November 16, 2009Date of Patent: June 14, 2011Assignee: Wyeth LLCInventors: Hsien-Jue Chu, Wumin Li, Zhichang Xu
-
Patent number: 7947309Abstract: Compositions are provided which include hyaluronic acid derivatives in combination with vaccine antigens, and optionally adjuvants, for mucosal delivery. Also provided are methods of making the compositions, as well as methods of immunization using the same.Type: GrantFiled: November 10, 2009Date of Patent: May 24, 2011Assignee: Fidia Farmaceutici S.p.AInventors: Derek O'Hagan, Alessandra Pavesio
-
Patent number: 7943147Abstract: Vaccine protection against acute or chronic viral infection is facilitated by using as an adjuvant or immuno-stimulant, a dsRNA together with an anti-influenza vaccine.Type: GrantFiled: December 6, 2006Date of Patent: May 17, 2011Assignee: Hemispherx BiopharmaInventors: William A. Carter, David Strayer
-
Publication number: 20110104202Abstract: The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.Type: ApplicationFiled: December 9, 2010Publication date: May 5, 2011Applicant: St. Jude Children's Research HospitalInventors: Erich Hoffmann, Aleksandr S. Lipatov, Richard J. Webby, Elena A. Govorkova, Robert G. Webster
-
Patent number: 7914797Abstract: The present invention relates to influenza vaccines for human and veterinary use. In particular, the present invention provides a vaccine able to effect long term and cross-strain protection by including at least two influenza virus epitopes expressed as a chimeric polypeptide wherein at least one epitope is influenza A virus matrix protein epitope and the second epitope is a haemagglutinin peptide epitope.Type: GrantFiled: December 6, 2006Date of Patent: March 29, 2011Assignee: Yeda Research and Development Co. Ltd. at the Weizmann Institute of ScienceInventors: Ruth Arnon, Tamar Ben-Yedidia
-
Publication number: 20110070263Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: August 17, 2010Publication date: March 24, 2011Applicant: MEDIMMUNE, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Patent number: 7871626Abstract: The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines.Type: GrantFiled: July 27, 2006Date of Patent: January 18, 2011Assignee: St. Jude Children's Research HospitalInventors: Erich Hoffmann, Aleksandr S. Lipatov, Richard J. Webby, Elena A. Govorkova, Robert G. Webster
-
Publication number: 20110002960Abstract: Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided.Type: ApplicationFiled: September 7, 2010Publication date: January 6, 2011Applicant: MEDIMMUNE, LLCInventors: Chin-Fen Yang, George Kemble, Chongguang Liu
-
Publication number: 20100330118Abstract: Polypeptides, polynucleotides, reassortant viruses, immunogenic compositions and vaccines comprising influenza hemagglutinin and neuraminidase variants and method using thereof are provided.Type: ApplicationFiled: February 3, 2010Publication date: December 30, 2010Applicants: MEDIMMUNE, LLC, The Government of the United States of America, National Institutes of HealthInventors: Hong JIN, Xing CHENG, Kanta SUBBARAO
-
Patent number: 7842295Abstract: The present invention provides an isolated canine influenza virus of subtype H3N8 comprising an HA having SEQ ID NO: 4 or an amino acid sequence that is greater than 99% identical to SEQ ID NO: 4, with the proviso that the amino acids at positions 94 and 233 are identical to SEQ ID NO: 4; a composition comprising attenuated or inactivated virus; isolated or purified HA, NM, NP, M1, NS1, PA, PB1, and PB2 proteins and fragments thereof and compositions comprising same or nucleic acids, optionally as part of a vector, encoding same; and a method of inducing an immune response to canine influenza virus in an animal comprising administering to the animal an aforementioned composition.Type: GrantFiled: September 15, 2008Date of Patent: November 30, 2010Assignee: Iowa State University Research Foundation, Inc.Inventors: Kyoung-Jin Yoon, Vickie Cooper
-
Publication number: 20100247569Abstract: The present invention includes compositions and methods related to the structure and function of the cellular polyadenylation and specificity factor 30 (CPSF30) binding site on the surface of the influenza A non-structural protein 1 (NS1). Specifically, critical biochemical reagents, conditions for crystallization and NMR analysis, assays, and general processes are described for (i) discovering, designing, and optimizing small molecule inhibitors of influenza A (avian flu) viruses and (ii) creating attenuated influenza virus strains suitable for avian and human flu vaccine development.Type: ApplicationFiled: February 17, 2010Publication date: September 30, 2010Applicant: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Gaetano Montelione, Kalyan Das, Edward Arnold, LiChung Ma, Rong Xiao, Robert M. Krug, Karen Y. Twu, Rei-Lin Kuo
-
Publication number: 20100233204Abstract: The present disclosure relates to multivalent immunogen compositions for treating or preventing diseases or disorders in canines caused by or associated with one or more of canine distemper virus, canine adenovirus (type 1 or type 2), canine parainfluenza virus, canine parvovirus, Leptospira canicola, Leptospira icterohaemorrhagiae, Leptospira grippotyphosa, Leptospira pomona, Leptospira bratislava, Leptospira hardjo, Leptospira autumnalis, Leptospira australis, Leptospira hebdomadis, and Bordetella bronchiseptica. The Leptospira compositions can also be used for treating or preventing leptospirosis diseases or disorders in canine, swine, and bovine.Type: ApplicationFiled: February 25, 2008Publication date: September 16, 2010Applicant: WYETHInventor: Michael Alonzo Gill